Literature DB >> 34157218

Natural history of small asymptomatic kidney and residual stones over a long-term follow-up: systematic review over 25 years.

Catherine E Lovegrove1,2, Robert M Geraghty3,4, Bingyuan Yang1, Eleanor Brain5, Sarah Howles1,2,6, Ben Turney1,2, Bhaskar Somani7.   

Abstract

OBJECTIVE: To systematically review the natural history of small asymptomatic kidney and residual stones, as the incidental identification of small, asymptomatic renal calculi has risen with increasing use of high-resolution imaging.
MATERIALS AND METHODS: We reviewed the natural history of small asymptomatic kidney and residual stones using the Cochrane and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) methodology. We searched MEDLINE, Scopus, EMBASE, EBSCO, Cochrane library and Clinicaltrials.gov using themes of 'asymptomatic', 'nephrolithiasis', 'observation', 'symptoms', 'admission', 'intervention' and similar allied terms for all English language articles from 1996 to 2020 (25 years). Inclusion criteria were studies with ≥50 patients, stones ≤10 mm, and a mean follow-up of ≥24 months. Primary outcomes were occurrence of symptoms, emergency admission, and interventions.
RESULTS: Our literature search returned 2247 results of which 10 papers were included in the final review. Risk of symptomatic episodes ranged from 0% to 59.4%. Meta-analysis did not identify any significant difference in the likelihood of developing symptoms when comparing stones <5 mm to those >5 mm, nor those <10 mm to those >10 mm. Risk of admission varied from 14% to 19% and the risk of intervention from 12% to 35%. Meta-analysis showed a significantly decreased likelihood of intervention for stones <5 vs >5 mm and <10 vs >10 mm. Studies had variable risk of bias due to heterogeneous reporting of outcome measures with significant likelihood that observed differences in results were compatible with chance alone (Symptoms: I2 =0%, Cochran's Q = 3.09, P = 0.69; Intervention: I2 =0%, Cochran's Q = 1.76, P = 0.88).
CONCLUSIONS: The present systematic review indicates that stone size is not a reliable predictor of symptoms; however, risk of intervention is greater for stones >5mm vs <5 mm and >10 vs <10 mm. This review will inform urologists as they discuss management strategies with patients who have asymptomatic renal stones and offer insight to committees during the development of evidence-based guidelines.
© 2021 The Authors. BJU International published by John Wiley & Sons Ltd on behalf of BJU International.

Entities:  

Keywords:  asymptomatic nephrolithiasis; intervention; surveillance; symptoms

Mesh:

Year:  2021        PMID: 34157218     DOI: 10.1111/bju.15522

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  4 in total

1.  Global Trends in Incidence and Burden of Urolithiasis from 1990 to 2019: An Analysis of Global Burden of Disease Study Data.

Authors:  Jacob Lang; Aparna Narendrula; Ahmed El-Zawahry; Puneet Sindhwani; Obi Ekwenna
Journal:  Eur Urol Open Sci       Date:  2022-01-03

2.  The Relationship Between Renal Stones and Primary Aldosteronism.

Authors:  Chun-Kai Chang; Chin-Chen Chang; Vin-Cent Wu; Jiun-Hung Geng; Hsiang-Ying Lee
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-09       Impact factor: 5.555

Review 3.  Optimal Delivery of Follow-Up Care for the Prevention of Stone Recurrence in Urolithiasis Patients: Improving Outcomes.

Authors:  Lazaros Tzelves; Marinos Berdempes; Panagiotis Mourmouris; Iraklis Mitsogiannis; Andreas Skolarikos
Journal:  Res Rep Urol       Date:  2022-04-19

4.  Technique, Feasibility, Utility, Limitations, and Future Perspectives of a New Technique of Applying Direct In-Scope Suction to Improve Outcomes of Retrograde Intrarenal Surgery for Stones.

Authors:  Vineet Gauhar; Bhaskar Kumar Somani; Chin Tiong Heng; Vishesh Gauhar; Ben Hall Chew; Kemal Sarica; Jeremy Yuen-Chun Teoh; Daniele Castellani; Mohammed Saleem; Olivier Traxer
Journal:  J Clin Med       Date:  2022-09-27       Impact factor: 4.964

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.